Market Cap 4.50B
Revenue (ttm) 0.00
Net Income (ttm) -252.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 15,312,200
Avg Vol 2,915,698
Day's Range N/A - N/A
Shares Out 82.32M
Stochastic %K 67%
Beta -0.40
Analysts Sell
Price Target $56.67

Company Profile

Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 487 6488
Website: akerotx.com
Address:
601 Gateway Boulevard, Suite 350, South San Francisco, United States
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 25 at 3:17 PM
Actionable Trade Alert for $AKRO: Market Context: $AKRO is currently trading at $54.65, near its 60-day high of $54.83. The RSI at 69.05 indicates overbought conditions, suggesting potential for a pullback. However, the price is above both the 30-day MA (54.29) and the 50-day MA (53.06), indicating a bullish trend. Directional Bias: The bullish trend is supported by the price being above the moving averages, but the high RSI suggests caution. The price is within a tight range, with the 60-day low at $41.80, indicating strong support below. Trade Plan: - Suggested Entry: $54.50 - Stop Loss: $53.50 (1.83% risk) - Take Profit Targets: 1. $56.00 (2.73% gain) 2. $57.50 (5.75% gain) 3. $64.00 (17% gain) This plan offers a favorable risk-reward ratio, targeting a significant return while managing risk effectively. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
DataLakeD
DataLakeD Dec. 25 at 11:31 AM
$AKRO The strategic path forward will be judged on practical milestones, not narrative strength. Cash generation and unit economics need to converge with strategy for the thesis to mature. Aligned incentives and governance can stabilize expectations. From here, delivery cadence—not ambition—will define investability.
0 · Reply
Thepatientone
Thepatientone Dec. 23 at 9:34 PM
$ALT BIC vs $AKRO , $ETNB , $MTSR , $MADRIG, $VKTX Altimmune is not “missing” anything. It has already cleared the Phase 3 gate and is now running a program that reflects modern regulatory thinking, not legacy dogma. None of the others have done such, no one.
2 · Reply
Thepatientone
Thepatientone Dec. 20 at 5:45 PM
$ALT BIC VS $AKRO , $89BIO, $MTSR , $MDGL , $VKTX Quality of weight loss: Yes (likely), subject to continued validation MASH resolution at 24 weeks: Yes (strong case) Cardiovascular health: Not proven yet (credible thesis, but still optionality) Tolerability / AE / discontinuations: Yes (strong case) NITs: Yes (strong case for coherence + durability) The one thing I’d add (even though you didn’t ask) If you’re comparing “superior treatment” in the full MASH regulatory sense, the open question remains: Biopsy-confirmed fibrosis improvement in a Phase 3-sized dataset at 48–52 weeks (and durability beyond)
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 5:12 PM
Actionable Trade Alert for $AKRO: Market Context: $AKRO is currently trading at $54.65, near its 60-day high of $54.83. The RSI at 69.05 indicates the stock is approaching overbought territory, suggesting potential caution. However, the stock remains above its 30-day moving average (MA30) of $54.29 and 50-day moving average (MA50) of $53.06, indicating a bullish trend. Directional Bias: The stock shows strong momentum but is close to the upper range of its recent trading history. The proximity to the 60-day high suggests potential resistance, while the solid support from MAs indicates a bullish bias. Trade Plan: - Suggested Entry: $54.65 - Stop Loss: $53.50 (1.5% below entry) - Take Profit Targets: 1. $56.00 (2.5% gain) 2. $57.00 (4.9% gain) 3. $64.00 (17% gain) This plan allows for a solid risk-reward ratio while targeting significant upside potential. Monitor RSI and price action closely for adjustments. https://privateprofiteers.com
0 · Reply
Power2k
Power2k Dec. 19 at 3:34 PM
$ALT Totally echoed you man. Instead of dumping more shares or pushing the exit button like all those short-sighted and inexperienced retail traders looking to get rich overnight, I loaded 600 more shares this morning at 4.02. Pemvidutide = best-in-class MASH drug on both counts of efficacy and safety. $LLY $AKRO $NVO
2 · Reply
outlawinvestor1
outlawinvestor1 Dec. 19 at 12:42 PM
$ALT $MDGL $AKRO $ETNB ignore the noise - the data are highly encouraging and competitive.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 3:58 AM
Actionable Trade Alert for $AKRO: Market Context: $AKRO is currently trading at $54.65, near its 60-day high of $54.83, indicating bullish momentum. The RSI of 69.05 suggests the stock is nearing overbought territory, which may lead to a pullback. However, the price is above both the 30-day MA of $54.29 and the 50-day MA of $53.06, reinforcing a bullish bias. Directional Bias: The stock shows strong upward momentum, but caution is warranted due to the high RSI. The proximity to the 60-day high suggests potential resistance. Trade Plan: - Suggested Entry: $54.70 (slightly above the last close to confirm upward movement) - Stop Loss: $53.80 (below the 30-day MA) - Take Profit Targets: 1. $55.50 (1.46% gain) 2. $56.00 (2.41% gain) 3. $64.00 (17% gain) This plan provides a clear path for profit while managing risk. Monitor closely for any signs of reversal. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 7:31 AM
$AKRO Actionable Trade Alert: Market Context: $AKRO is currently trading at $54.65, near its 60-day high of $54.83. The RSI at 69.05 indicates that the stock is approaching overbought territory, suggesting a potential pullback or consolidation. Directional Bias: The stock shows bullish momentum with the 30-day MA at $54.29 and the 50-day MA at $53.06, both indicating upward trends. However, the RSI signals caution due to its elevated level. Trade Plan: - Suggested Entry: $54.50 - Stop Loss: $53.50 (1.83% below entry) - Take Profit Targets: 1. TP1: $55.50 (1.83% gain) 2. TP2: $57.00 (4.26% gain) 3. TP3: $64.00 (17% gain) Rationale: The targets are set based on the recent high and potential breakout levels. The stop loss is placed to limit downside risk while allowing for potential upside. Monitor RSI for signs of reversal as targets are approached. https://privateprofiteers.com
0 · Reply
Power2k
Power2k Dec. 14 at 5:44 PM
$ALT I think a main reason Novo and Roche bought $AKRO and $ETNB is to pair FGF21s with their current or future GLP-1s in some sort of combo therapy. But, how would they deal with the added side effects coming from both entities? The discontinuation due to AEs is going to be ENORMOUS. In contrast, Pemvi is a Combo by itself: weight loss + MASH resolution (with two bonuses: Lean Mass Preservation and NO titrations needed).
0 · Reply
Latest News on AKRO
My Top 3 Pharma Stocks

Oct 20, 2025, 11:38 AM EDT - 2 months ago

My Top 3 Pharma Stocks

BMY ETNB LLY MRK NVO PFE SPY


Akero Therapeutics Stock Soars on Novo Nordisk Deal.

Oct 9, 2025, 7:31 AM EDT - 2 months ago

Akero Therapeutics Stock Soars on Novo Nordisk Deal.

NVO


Novo Nordisk To Buy Akero Therapeutics for $4.7 Billion

Oct 9, 2025, 6:39 AM EDT - 2 months ago

Novo Nordisk To Buy Akero Therapeutics for $4.7 Billion

NVO


Novo Nordisk buys Akero Therapeutics in the US

Oct 9, 2025, 6:09 AM EDT - 2 months ago

Novo Nordisk buys Akero Therapeutics in the US

NVO


Akero Therapeutics: Cirrhosis Reversal Data Derisks The Stock

Apr 6, 2025, 1:47 PM EDT - 9 months ago

Akero Therapeutics: Cirrhosis Reversal Data Derisks The Stock


PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 25 at 3:17 PM
Actionable Trade Alert for $AKRO: Market Context: $AKRO is currently trading at $54.65, near its 60-day high of $54.83. The RSI at 69.05 indicates overbought conditions, suggesting potential for a pullback. However, the price is above both the 30-day MA (54.29) and the 50-day MA (53.06), indicating a bullish trend. Directional Bias: The bullish trend is supported by the price being above the moving averages, but the high RSI suggests caution. The price is within a tight range, with the 60-day low at $41.80, indicating strong support below. Trade Plan: - Suggested Entry: $54.50 - Stop Loss: $53.50 (1.83% risk) - Take Profit Targets: 1. $56.00 (2.73% gain) 2. $57.50 (5.75% gain) 3. $64.00 (17% gain) This plan offers a favorable risk-reward ratio, targeting a significant return while managing risk effectively. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
DataLakeD
DataLakeD Dec. 25 at 11:31 AM
$AKRO The strategic path forward will be judged on practical milestones, not narrative strength. Cash generation and unit economics need to converge with strategy for the thesis to mature. Aligned incentives and governance can stabilize expectations. From here, delivery cadence—not ambition—will define investability.
0 · Reply
Thepatientone
Thepatientone Dec. 23 at 9:34 PM
$ALT BIC vs $AKRO , $ETNB , $MTSR , $MADRIG, $VKTX Altimmune is not “missing” anything. It has already cleared the Phase 3 gate and is now running a program that reflects modern regulatory thinking, not legacy dogma. None of the others have done such, no one.
2 · Reply
Thepatientone
Thepatientone Dec. 20 at 5:45 PM
$ALT BIC VS $AKRO , $89BIO, $MTSR , $MDGL , $VKTX Quality of weight loss: Yes (likely), subject to continued validation MASH resolution at 24 weeks: Yes (strong case) Cardiovascular health: Not proven yet (credible thesis, but still optionality) Tolerability / AE / discontinuations: Yes (strong case) NITs: Yes (strong case for coherence + durability) The one thing I’d add (even though you didn’t ask) If you’re comparing “superior treatment” in the full MASH regulatory sense, the open question remains: Biopsy-confirmed fibrosis improvement in a Phase 3-sized dataset at 48–52 weeks (and durability beyond)
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 5:12 PM
Actionable Trade Alert for $AKRO: Market Context: $AKRO is currently trading at $54.65, near its 60-day high of $54.83. The RSI at 69.05 indicates the stock is approaching overbought territory, suggesting potential caution. However, the stock remains above its 30-day moving average (MA30) of $54.29 and 50-day moving average (MA50) of $53.06, indicating a bullish trend. Directional Bias: The stock shows strong momentum but is close to the upper range of its recent trading history. The proximity to the 60-day high suggests potential resistance, while the solid support from MAs indicates a bullish bias. Trade Plan: - Suggested Entry: $54.65 - Stop Loss: $53.50 (1.5% below entry) - Take Profit Targets: 1. $56.00 (2.5% gain) 2. $57.00 (4.9% gain) 3. $64.00 (17% gain) This plan allows for a solid risk-reward ratio while targeting significant upside potential. Monitor RSI and price action closely for adjustments. https://privateprofiteers.com
0 · Reply
Power2k
Power2k Dec. 19 at 3:34 PM
$ALT Totally echoed you man. Instead of dumping more shares or pushing the exit button like all those short-sighted and inexperienced retail traders looking to get rich overnight, I loaded 600 more shares this morning at 4.02. Pemvidutide = best-in-class MASH drug on both counts of efficacy and safety. $LLY $AKRO $NVO
2 · Reply
outlawinvestor1
outlawinvestor1 Dec. 19 at 12:42 PM
$ALT $MDGL $AKRO $ETNB ignore the noise - the data are highly encouraging and competitive.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 3:58 AM
Actionable Trade Alert for $AKRO: Market Context: $AKRO is currently trading at $54.65, near its 60-day high of $54.83, indicating bullish momentum. The RSI of 69.05 suggests the stock is nearing overbought territory, which may lead to a pullback. However, the price is above both the 30-day MA of $54.29 and the 50-day MA of $53.06, reinforcing a bullish bias. Directional Bias: The stock shows strong upward momentum, but caution is warranted due to the high RSI. The proximity to the 60-day high suggests potential resistance. Trade Plan: - Suggested Entry: $54.70 (slightly above the last close to confirm upward movement) - Stop Loss: $53.80 (below the 30-day MA) - Take Profit Targets: 1. $55.50 (1.46% gain) 2. $56.00 (2.41% gain) 3. $64.00 (17% gain) This plan provides a clear path for profit while managing risk. Monitor closely for any signs of reversal. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 7:31 AM
$AKRO Actionable Trade Alert: Market Context: $AKRO is currently trading at $54.65, near its 60-day high of $54.83. The RSI at 69.05 indicates that the stock is approaching overbought territory, suggesting a potential pullback or consolidation. Directional Bias: The stock shows bullish momentum with the 30-day MA at $54.29 and the 50-day MA at $53.06, both indicating upward trends. However, the RSI signals caution due to its elevated level. Trade Plan: - Suggested Entry: $54.50 - Stop Loss: $53.50 (1.83% below entry) - Take Profit Targets: 1. TP1: $55.50 (1.83% gain) 2. TP2: $57.00 (4.26% gain) 3. TP3: $64.00 (17% gain) Rationale: The targets are set based on the recent high and potential breakout levels. The stop loss is placed to limit downside risk while allowing for potential upside. Monitor RSI for signs of reversal as targets are approached. https://privateprofiteers.com
0 · Reply
Power2k
Power2k Dec. 14 at 5:44 PM
$ALT I think a main reason Novo and Roche bought $AKRO and $ETNB is to pair FGF21s with their current or future GLP-1s in some sort of combo therapy. But, how would they deal with the added side effects coming from both entities? The discontinuation due to AEs is going to be ENORMOUS. In contrast, Pemvi is a Combo by itself: weight loss + MASH resolution (with two bonuses: Lean Mass Preservation and NO titrations needed).
0 · Reply
Power2k
Power2k Dec. 14 at 3:43 PM
$ALT Good analysis and comparison. This tells me given longer treatment window (ie >=48 wks), Pemvi will definitely show stat sig fibrosis improvement vs Placebo. Pemvi is way superior to all FGF21s and THR-beta agonists in terms of MASH resolution (early onset at 24wk) and safety (low AE and drop-out rates) profiles, plus weight-loss benefits and no titrations needed. $AKRO $RHHBY $MDGL
1 · Reply
outlawinvestor1
outlawinvestor1 Dec. 14 at 3:30 PM
$ALT $AKRO $NVO i reviewed both articles (and company presentations) and present a comparison table of the trial data below. note: the patient number, discontinuation rate, and neither trial showed stat sig for fibrosis at 24 weeks. akero was purchased by novo for up to $5.2B in october. 😊 *this strictly uses ITT analysis for mash resolution and fibrosis improvement (the conservative calculation method).
1 · Reply
outlawinvestor1
outlawinvestor1 Dec. 14 at 10:58 AM
$ALT noureddin is an influential physician-scientist in metabolic disorder treatments. $AKRO efruxifermin was purchsed by $NVO a few months after lancet publication. https://www.thelancet.com/authored-by/Noureddin/Mazen
3 · Reply
H8shorts
H8shorts Dec. 12 at 11:28 AM
$AKRO why are these still trading? Shouldn't this be nvo shares now???
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 12 at 12:24 AM
Actionable Trade Alert for $AKRO: Market Context: $AKRO is currently trading at $54.65, showing strong momentum with an RSI of 69.05, indicating it is nearing overbought territory. The stock is above its 30-day MA of $54.29 and 50-day MA of $53.06, suggesting bullish sentiment. The recent 60-day high of $54.83 is just above the current price, providing a potential resistance level. Directional Bias: Given the current price is near the 60-day high, we anticipate a breakout or pullback. The RSI indicates strength, but caution is warranted due to its elevated level. Trade Plan: - Suggested Entry: $54.70 (slightly above current close to capture momentum) - Stop Loss: $53.50 (to limit downside risk) - Take Profit Targets: 1. $55.50 (1.5% gain) 2. $56.50 (3.5% gain) 3. $64.00 (17% gain) This plan allows for a favorable risk-reward ratio, targeting significant upside while managing risk effectively. https://privateprofiteers.com
0 · Reply
HOSTS777
HOSTS777 Dec. 11 at 9:19 PM
$AKRO merger complete now just waiting for the cvr to hit whenever it will
0 · Reply
Dark_Horse_Investments
Dark_Horse_Investments Dec. 10 at 8:23 PM
$AKRO Getting paid - let get that $6 CVR in the future.
0 · Reply
Cmeek2022
Cmeek2022 Dec. 10 at 7:46 PM
$AKRO what’s going on here ? How do I find my shares of akro?
0 · Reply
BioTechHealthX
BioTechHealthX Dec. 10 at 4:16 PM
$NVO $AKRO Nordisk (NVO) has officially acquired Akero Therapeutics (AKRO) for $54 per share plus a $6 CVR, totaling up to $5.2 billion. With EFX now under Novo’s control and a massive MASH market ahead, analysts say this deal could redefine the global obesity and metabolic disease landscape. https://biotechhealthx.com/biotech-news/nvo-stock-alert-novo-nordisk-nvo-just-bought-akero-akro-for-4-7b-and-it-may-have-secured-the-next-blockbuster-drug/
0 · Reply
JarvisFlow
JarvisFlow Dec. 10 at 1:56 PM
Cantor Fitzgerald updates rating for Akero Therapeutics ( $AKRO ) to Overweight.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 4:27 AM
Actionable Trade Alert for $AKRO: Market Context: $AKRO is currently trading at $54.65, near its 60D high of $54.83, indicating bullish momentum. The RSI at 69.05 suggests that the stock is nearing overbought territory, which may lead to a pullback or consolidation before further upward movement. Directional Bias: The stock is above its 30-day moving average (MA30) of $54.29 and the 50-day moving average (MA50) of $53.06, indicating a strong bullish trend. The proximity to the 60D high reinforces a positive outlook, but caution is warranted due to the high RSI. Trade Plan: - Suggested Entry: $54.70 (slightly above the last close to confirm momentum) - Stop Loss: $53.50 (to limit downside risk) - Take Profit Targets: 1. $56.00 (4.9% gain) 2. $57.50 (5.8% gain) 3. $64.00 (17.0% gain) This plan aims for a significant ROI on the third target while managing risk effectively. https://privateprofiteers.com
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 10 at 2:28 AM
$AKRO Current Stock Price: $54.65 Contracts to trade: $55 AKRO Dec 19 2025 Call Entry: $0.05 Exit: $0.08 ROI: 79% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply